Drugs / PentixaFor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05499637 | Jan 2023 → Dec 2026 expected | acute transplant rejection, cardiac sarcoidosis, toxic myocarditis | John O. Prior | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PentixaFor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05499637 ↗ |
| Route | Intravenous | “50 µg IV PentixaFor” NCT05499637 ↗ |